Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) is expected to be releasing its earnings data before the market opens on Thursday, March 27th. Analysts expect Vivos Therapeutics to post earnings of ($0.43) per share and revenue of $3.89 million for the quarter.
Vivos Therapeutics Trading Down 0.6 %
Shares of VVOS opened at $3.53 on Thursday. The stock has a fifty day moving average price of $4.03 and a 200-day moving average price of $3.57. Vivos Therapeutics has a 12 month low of $1.91 and a 12 month high of $6.28. The firm has a market cap of $20.79 million, a PE ratio of -0.62 and a beta of 7.47.
Analysts Set New Price Targets
Separately, Ascendiant Capital Markets restated a “buy” rating and set a $6.60 price target on shares of Vivos Therapeutics in a research note on Wednesday, November 20th.
Vivos Therapeutics Company Profile
Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.
Featured Articles
- Five stocks we like better than Vivos Therapeutics
- 5 discounted opportunities for dividend growth investors
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- What is the S&P/TSX Index?
- Alphabet’s Officially In A Bear Market—Time To Buy?
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
